Ve study research aiming at acquiring a superior remedy for curing this disease. One of the quite a few approaches is by enhancing the delivery of anticancer drugs towards cancer cells applying advanced technologies. In this assessment, we focused on docetaxel as among essentially the most frequently made use of drugs for lung cancer treatment and discussed the properties of your drug as well as the application of nanotechnology in delivering this drug to improve its efficacy and specificity although decreasing its negative effects. Abstract: Docetaxel (DCX) is really a highly efficient chemotherapeutic drug made use of within the treatment of distinct varieties of cancer, which includes non-small cell lung cancer (NSCLC). The drug is recognized to possess low oral bioavailability as a result of its low aqueous solubility, poor membrane permeability and susceptibility to hepatic first-pass metabolism. To mitigate these complications, DCX is administered through the intravenous route. At present, DCX is commercially obtainable as a single vial that includes polysorbate 80 and ethanol to solubilize the poorly soluble drug. Even so, this formulation causes shortand long-term unwanted side effects, which includes hypersensitivity, febrile neutropenia, fatigue, fluid retention, and peripheral neuropathy. DCX can also be a substrate towards the drug efflux pump P-glycoprotein (P-gp) that would lessen its concentration within the vicinity of the cells and bring about the improvement of drug resistance. Hence, the incorporation of DCX into different nanocarrier systems has garnered a ADAM10 web significant quantity of attention in recent years to overcome these drawbacks. The surfaces of those drug-delivery systems certainly could be functionalized by modification with distinct ligands for sensible targeting towards cancerous cells. This short article provides an overview on the latest nanotechnological approaches and the delivery systems that were developed for passive and active delivery of DCX by way of diverse routes of administration for the treatment of lung cancer. Keywords: docetaxel; nanoparticles; lung cancer; drug delivery; non-small cell lung cancer (NSCLC)Citation: A. Razak, S.A.; Mohd Gazzali, A.; Fisol, F.A.; M. Abdulbaqi, I.; Parumasivam, T.; Mohtar, N.; A. Wahab, H. Advances in Nanocarriers for Efficient Delivery of Docetaxel within the Treatment of Lung Cancer: An Overview. Cancers 2021, 13, 400. https://doi.org/10.3390/ cancers13030400 Academic Editor: Samuel Mok Received: 12 November 2020 Accepted: 24 December 2020 Published: 22 January 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in Published maps and institutional affiliations.1. Introduction Amongst all types of cancers, lung cancer would be the most usually diagnosed in both males and females globally and also the major reason for cancer-related deaths [1]. Investigation research are constantly carried out to seek out a greater remedy in treating lung cancer because the current therapy regimen usually connected with nonspecific and nonselective cytotoxic chemotherapy or surgery. There are lots of classes of drugs which have been authorized by the United states Food and Drug Administration (US FDA) to treat lung cancer, and among the usually utilised ones could be the antineoplastic taxane: docetaxel (DCX). Docetaxel, discovered by Pierre Potier in National Center for Scientific Analysis in France through the 1980s, belongs for the taxoid class of cytotoxic agents Bfl-1 site together withCopyright: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This short article is definitely an open access write-up distributed below the terms and situations from the Cr.
